Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marc B Garnick

Showing results (21-30 of 41) with videos related to

Pageof 5
Sort By:
Urology|September 7, 2021
EDITORIAL COMMENTMarc B Garnick, Aria Olumi
Urology|July 17, 2022
EDITORIAL COMMENTMarc B Garnick, Andrew A Wagner
Urology Practice|December 20, 2023
Editorial CommentMarc B Garnick, E David Crawford
Urology|August 24, 2025
Editorial Comment on "Prostate Specific Antigen Testing and Prostate Cancer Diagnosis Rates Among Transgender and Nonbinary Patients: Retrospective Review of a Single-Institution Experience"Marc B Garnick, Marissa A Kent
Urology|August 28, 2019
EDITORIAL COMMENTMarc B Garnick, David J Einstein
Urology|November 10, 2020
EDITORIAL COMMENTMarc B Garnick, David J Einstein
Future Oncology (London, England)|December 13, 2006
Abarelix for injectable suspension: first-in-class gonadotropin-releasing hormone antagonist for prostate cancerFrans Debruyne, Gajanan Bhat, Marc B Garnick
The Journal of Urology|January 5, 2024
Reply: Cardiovascular Risk in Prostate Cancer Patients Using Luteinizing Hormone-Releasing Hormone Agonists or a Gonadotropin-Releasing Hormone AntagonistMarc B Garnick, Jason Hafron, E David Crawford
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 25, 2025
First-Line [<sup>177</sup>Lu]Lu-PSMA-617 Therapy Without ADT, Chemotherapy, or Local Therapy for Metastatic Hormone-Sensitive Prostate CancerVinay K Giri, Gerald M Kolodny, Marc B Garnick
The Journal of Urology|July 4, 2006
The effect of androgen deprivation therapy on fasting serum lipid and glucose parametersJennifer Yannucci, Judi Manola, Marc B Garnick, et al.
Pageof 5

Showing results (21-30 of 41) with videos related to

Sort By:
Pageof 5
Urology|September 7, 2021
EDITORIAL COMMENTMarc B Garnick, Aria Olumi
Urology|July 17, 2022
EDITORIAL COMMENTMarc B Garnick, Andrew A Wagner
Urology Practice|December 20, 2023
Editorial CommentMarc B Garnick, E David Crawford
Urology|August 24, 2025
Editorial Comment on "Prostate Specific Antigen Testing and Prostate Cancer Diagnosis Rates Among Transgender and Nonbinary Patients: Retrospective Review of a Single-Institution Experience"Marc B Garnick, Marissa A Kent
Urology|August 28, 2019
EDITORIAL COMMENTMarc B Garnick, David J Einstein
Urology|November 10, 2020
EDITORIAL COMMENTMarc B Garnick, David J Einstein
Future Oncology (London, England)|December 13, 2006
Abarelix for injectable suspension: first-in-class gonadotropin-releasing hormone antagonist for prostate cancerFrans Debruyne, Gajanan Bhat, Marc B Garnick
The Journal of Urology|January 5, 2024
Reply: Cardiovascular Risk in Prostate Cancer Patients Using Luteinizing Hormone-Releasing Hormone Agonists or a Gonadotropin-Releasing Hormone AntagonistMarc B Garnick, Jason Hafron, E David Crawford
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 25, 2025
First-Line [<sup>177</sup>Lu]Lu-PSMA-617 Therapy Without ADT, Chemotherapy, or Local Therapy for Metastatic Hormone-Sensitive Prostate CancerVinay K Giri, Gerald M Kolodny, Marc B Garnick
The Journal of Urology|July 4, 2006
The effect of androgen deprivation therapy on fasting serum lipid and glucose parametersJennifer Yannucci, Judi Manola, Marc B Garnick, et al.
Pageof 5